Systematic analysis of off-label and off-guideline cancer therapy usage in a real-world cohort of 165,912 US patients
Ruishan Liu, Lisa Wang, Shemra Rizzo, Marius Garmhausen, Navdeep Pal, Sarah Waliany, Sarah F. McGough, Yvonne G. Lin, Zhi Huang, Joel W. Neal, Ryan Copping, James Zou
Abstract
Patients with cancer may be given treatments that are not officially approved (off-label) or recommended by guidelines (off-guideline). Here we present a data science framework to systematically characterize off-label and off-guideline usages using real-world data from de-identified electronic health records (EHR). We analyze treatment patterns in 165,912 US patients with 14 common cancer types. We find that 18.6% and 4.4% of patients have received at least one line of off-label and off-guideline cancer drugs, respectively. Patients with worse performance status, in later lines, or treated at academic hospitals are significantly more likely to receive off-label and off-guideline drugs. To quantify how predictable off-guideline usage is, we developed machine learning models to predict which drug a patient is likely to receive based on their clinical characteristics and previous treatments. Finally, we demonstrate that our systematic analyses generate hypotheses about patients' response to treatments.